Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier

Shariati, Ali; Nemati, Reza; Sadeghipour, Yasin; Yaghoubi, Yoda; Baghbani, Reza; Javidi, Kamran; Zamani, Majid; Hassanzadeh, Ali

doi:10.1016/j.ejcb.2020.151097

Cited by 67 publications

(39 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs can supposedly be isolated from any human tissue, while there exist concrete restrictions based on the availability of source tissues and invasiveness of the isolation procedures and also different donor's features. It is of paramount importance to select a fitting cell source, evaluate the difficulty of samples procurement process, and consider the possible untoward effects of collecting cells from donors [23,24]. For instance, obtaining MSCs from BM can result in pain, bleeding, or infection, thereby making it more challenging than isolation from PB or surgical remnants (e.g., AT, DP, and UC) [25].…”

Section: Sources Of Mesenchymal Stem/stromal Cells (Mscs)mentioning

confidence: 99%

RETRACTED ARTICLE: Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders

et al. 2021

Self Cite

View full text Add to dashboard Cite

Over recent years, mesenchymal stem/stromal cells (MSCs) and their potential biomedical applications have received much attention from the global scientific community in an increasing manner. Firstly, MSCs were successfully isolated from human bone marrow (BM), but in the next steps, they were also extracted from other sources, mostly from the umbilical cord (UC) and adipose tissue (AT). The International Society for Cellular Therapy (ISCT) has suggested minimum criteria to identify and characterize MSCs as follows: plastic adherence, surface expression of CD73, D90, CD105 in the lack of expression of CD14, CD34, CD45, and human leucocyte antigen-DR (HLA-DR), and also the capability to differentiate to multiple cell types including adipocyte, chondrocyte, or osteoblast in vitro depends on culture conditions. However, these distinct properties, including self-renewability, multipotency, and easy accessibility are just one side of the coin; another side is their huge secretome which is comprised of hundreds of mediators, cytokines, and signaling molecules and can effectively modulate the inflammatory responses and control the infiltration process that finally leads to a regulated tissue repair/healing or regeneration process. MSC-mediated immunomodulation is a direct result of a harmonic synergy of MSC-released signaling molecules (i.e., mediators, cytokines, and chemokines), the reaction of immune cells and other target cells to those molecules, and also feedback in the MSC-molecule-target cell axis. These features make MSCs a respectable and eligible therapeutic candidate to be evaluated in immune-mediated disorders, such as graft versus host diseases (GVHD), multiple sclerosis (MS), Crohn’s disease (CD), and osteoarthritis (OA), and even in immune-dysregulating infectious diseases such as the novel coronavirus disease 2019 (COVID-19). This paper discussed the therapeutic applications of MSC secretome and its biomedical aspects related to immune-mediated conditions. Sources for MSC extraction, their migration and homing properties, therapeutic molecules released by MSCs, and the pathways and molecular mechanisms possibly involved in the exceptional immunoregulatory competence of MSCs were discussed. Besides, the novel discoveries and recent findings on immunomodulatory plasticity of MSCs, clinical applications, and the methods required for their use as an effective therapeutic option in patients with immune-mediated/immune-dysregulating diseases were highlighted.

show abstract

Section: Sources Of Mesenchymal Stem/stromal Cells (Mscs)mentioning

confidence: 99%

RETRACTED ARTICLE: Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mesenchymal stem/stromal cells (MSCs) are unique cell populations showing a large potential for unrestricted self-renewal, differentiating into a wide variety of diverse cell lines and forming distinct colonies [1][2][3]. They are multipotent fibroblast-like stem cells typically found in a variety of human tissue, including bone marrow (BM), adipose tissue, liver, intestine, lung, connective muscle tissue, spleen, skin, placenta, umbilical cords, and other tissues [4][5][6]. Currently, excellent progress has been established in stem cell technology with promising therapeutic possibilities for the treatment of various diseases [7].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities

et al. 2021

Self Cite

View full text Add to dashboard Cite

Recently, mesenchymal stem/stromal cells (MSCs) and their widespread biomedical applications have attracted great consideration from the scientific community around the world. However, reports have shown that the main populations of the transplanted MSCs are trapped in the liver, spleen, and lung upon administration, highlighting the importance of the development of cell-free therapies. Concerning rising evidence suggesting that the beneficial effects of MSC therapy are closely linked to MSC-released components, predominantly MSC-derived exosomes, the development of an MSC-based cell-free approach is of paramount importance. The exosomes are nano-sized (30–100 nm) lipid bilayer membrane vesicles, which are typically released by MSCs and are found in different body fluids. They include various bioactive molecules, such as messenger RNA (mRNA), microRNAs, proteins, and bioactive lipids, thus showing pronounced therapeutic competence for tissues recovery through the maintenance of their endogenous stem cells, the enhancement of regenerative phenotypic traits, inhibition of apoptosis concomitant with immune modulation, and stimulation of the angiogenesis. Conversely, the specific roles of MSC exosomes in the treatment of various tumors remain challenging. The development and clinical application of novel MSC-based cell-free strategies can be supported by better understanding their mechanisms, classifying the subpopulation of exosomes, enhancing the conditions of cell culture and isolation, and increasing the production of exosomes along with engineering exosomes to deliver drugs and therapeutic molecules to the target sites. In the current review, we deliver a brief overview of MSC-derived exosome biogenesis, composition, and isolation methods and discuss recent investigation regarding the therapeutic potential of MSC exosomes in regenerative medicine accompanied by their double-edged sword role in cancer.

show abstract

“…Neurodegenerative diseases are a heterogeneous group of disorders identified by the progressive degeneration or death of neurons in the brain or spinal cord (Shariati et al., 2020). Acute neurodegeneration is mainly caused by a temporally separate brain hemorrhage, triggering mainly restricted loss of neurons at the lesioned area (Allan & Rothwell, 2001).…”

Section: Introductionmentioning

confidence: 99%

Stem cell in neurodegenerative disorders; an emerging strategy

Ahani-Nahayati

Shariati

Mahmoodi

et al. 2021

Intl J of Devlp Neuroscience

Self Cite

View full text Add to dashboard Cite

Neurodegenerative disorders are a diversity of disorders, surrounding Alzheimer's (AD), Parkinson's (PD), Huntington's diseases (HD), and amyotrophic lateral sclerosis (ALS) accompanied by some other less common diseases generally characterized by either developed deterioration of central or peripheral nervous system structurally or functionally. Today, with the viewpoint of an increasingly aging society, the number of patients with neurodegenerative diseases and sociomedical burdens will spread intensely. During the last decade, stem cell technology has attracted great attention for treating neurodegenerative diseases worldwide because of its unique attributes. As acknowledged, there are several categories of stem cells being able to proliferate and differentiate into various cellular lineages, highlighting their significance in the context of regenerative medicine. In preclinical models, stem cell therapy using mesenchymal stem/stromal cells (MSCs), hematopoietic stem cells (HSCs), and neural progenitor or stem cells (NPCs or NSCs) along with pluripotent stem cells (PSCs)‐derived neuronal cells could elicit desired therapeutic effects, enabling functional deficit rescue partially. Regardless of the noteworthy progress in our scientific awareness and understanding of stem cell biology, there still exist various challenges to defeat. In the present review, we provide a summary of the therapeutic potential of stem cells and discuss the current status and prospect of stem cell strategy in neurodegenerative diseases, in particular, AD, PD, ALS, and HD.

show abstract

Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier

Cited by 67 publications

References 188 publications

RETRACTED ARTICLE: Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders

RETRACTED ARTICLE: Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders

Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities

Stem cell in neurodegenerative disorders; an emerging strategy

Contact Info

Product

Resources

About